APTAMER SCIENCES INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,750 KRW | +3.19% |
|
+4.56% | -23.72% |
| Sales 2022 | 358M 260K 20.85M | Sales 2023 | 243M 177K 14.16M | Capitalization | 61.21B 44.5M 3.56B |
|---|---|---|---|---|---|
| Net income 2022 | -7.12B -5.17M -414M | Net income 2023 | -13.6B -9.89M -792M | EV / Sales 2022 | 128 x |
| Net cash position 2022 | 28.47B 20.69M 1.66B | Net cash position 2023 | 15.5B 11.27M 903M | EV / Sales 2023 | 188 x |
| P/E ratio 2022 |
-10.4
x | P/E ratio 2023 |
-4.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.19% | ||
| 1 week | +4.56% | ||
| Current month | -16.41% | ||
| 1 month | -21.54% | ||
| 3 months | -7.56% | ||
| 6 months | -23.50% | ||
| Current year | -23.72% |
1 week
2 625.00
3 080.00
1 month
2 400.003 405.00
Current year
2 400.004 190.00
1 year
2 400.006 080.00
3 years
2 400.0014 000.00
5 years
2 400.0019 175.00
10 years
2 400.0019 175.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dong-Il Han
CEO | Chief Executive Officer | - | 31/12/10 |
Sung-Ho Ryu
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/10 |
Young-Ki Yoon
BRD | Director/Board Member | 54 | 31/08/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Ho Ryu
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/10 |
Dong-Il Han
CEO | Chief Executive Officer | - | 31/12/10 |
Seung-Ki Jang
BRD | Director/Board Member | - | 31/12/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2,750 | +3.19% | 31,351 |
| 25/04/24 | 2,665 | -2.56% | 29,567 |
| 24/04/24 | 2,735 | +4.19% | 355,894 |
| 23/04/24 | 2,625 | -1.32% | 16,782 |
| 22/04/24 | 2,660 | +1.14% | 15,841 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Aptamer Sciences Inc is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The Company provides services include aptamer synthesis and aptamer discovery. The Company also develops biopharmaceuticals such as insulin substitutes, insulin sensitizers, and liver cancer drugs. In addition, the Company also produces lung cancer diagnostic kits.
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.72% | 33.93M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- A291650 Stock
